Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Haruo Usuda is active.

Publication


Featured researches published by Haruo Usuda.


American Journal of Obstetrics and Gynecology | 2016

Outside-in? Acute fetal systemic inflammation in very preterm chronically catheterized sheep fetuses is not driven by cells in the fetal blood

Matthew W. Kemp; Timothy J. Molloy; Haruo Usuda; Eleanor Woodward; Yuichiro Miura; Matthew S. Payne; Demelza J. Ireland; Alan H. Jobe; Suhas G. Kallapur; Sarah J. Stock; Owen Bradley Spiller; John P. Newnham; Masatoshi Saito

BACKGROUND The preterm birth syndrome (delivery before 37 weeks gestation) is a major contributor to the global burden of perinatal morbidity and death. The cause of preterm birth is complex, multifactorial, and likely dependent, at least in part, on the gestational age of the fetus. Intrauterine infection is frequent in preterm deliveries that occur at <32 weeks gestation; understanding how the fetus responds to proinflammatory insult will be an important step towards early preterm birth prevention. However, animal studies of infection and inflammation in prematurity commonly use older fetuses that possess comparatively mature immune systems. OBJECTIVE Aiming to characterize acute fetal responses to microbial agonist at a clinically relevant gestation, we used 92-day-old fetuses (62% of term) to develop a chronically catheterized sheep model of very preterm pregnancy. We hypothesized that any acute fetal systemic inflammatory responses would be driven by signaling from the tissues exposed to Escherichia coli lipopolysaccharide that is introduced into the amniotic fluid. STUDY DESIGN Eighteen ewes that were carrying a single fetus at 92 days of gestation had recovery surgery to place fetal tracheal, jugular, and intraamniotic catheters. Animals were recovered for 24 hours before being administered either intraamniotic E coli lipopolysaccharide (n = 9) or sterile saline solution (n = 9). Samples were collected for 48 hours before euthanasia and necroscopy. Fetal inflammatory responses were characterized by microarray analysis, quantitative polymerase chain reaction, and enzyme-linked immunosorbent assay. RESULTS Intraamniotic lipopolysaccharide reached the distal trachea within 2 hours. Lipopolysaccharide increased tracheal fluid interleukin-8 within 2 hours and generated a robust inflammatory response that was characterized by interleukin-6 signaling pathway activation and up-regulation of cell proliferation but no increases in inflammatory mediator expression in cord blood RNA. CONCLUSIONS In very preterm sheep fetuses, lipopolysaccharide stimulates inflammation in the fetal lung and fetal skin and stimulates a systemic inflammatory response that is not generated by fetal blood cells. These data argue for amniotic fluid-exposed tissues that play a key role in driving acute fetal and intrauterine inflammatory responses.


Artificial Organs | 2016

A Parallelized Pumpless Artificial Placenta System Significantly Prolonged Survival Time in a Preterm Lamb Model

Yuichiro Miura; Tadashi Matsuda; Haruo Usuda; Shimpei Watanabe; Ryuta Kitanishi; Masatoshi Saito; Takushi Hanita; Yoshiyasu Kobayashi

An artificial placenta (AP) is an arterio-venous extracorporeal life support system that is connected to the fetal circulation via the umbilical vasculature. Previously, we published an article describing a pumpless AP system with a small priming volume. We subsequently developed a parallelized system, hypothesizing that the reduced circuit resistance conveyed by this modification would enable healthy fetal survival time to be prolonged. We conducted experiments using a premature lamb model to test this hypothesis. As a result, the fetal survival period was significantly prolonged (60.4 ± 3.8 vs. 18.2 ± 3.2 h, P < 0.01), and circuit resistance and minimal blood lactate levels were significantly lower in the parallel circuit group, compared with our previous single circuit group. Fetal physiological parameters remained stable until the conclusion of the experiments. In summary, parallelization of the AP system was associated with reduced circuit resistance and lactate levels and allowed preterm lamb fetuses to survive for a significantly longer period when compared with previous studies.


PLOS ONE | 2015

Ex-Vivo Uterine Environment (EVE) Therapy Induced Limited Fetal Inflammation in a Premature Lamb Model.

Yuichiro Miura; Masatoshi Saito; Haruo Usuda; Eleanor Woodward; Judith Rittenschober-Böhm; Paranthaman S. Kannan; Gabrielle C. Musk; Tadashi Matsuda; John P. Newnham; Matthew W. Kemp

Introduction Ex-vivo uterine environment (EVE) therapy uses an artificial placenta to provide gas exchange and nutrient delivery to a fetus submerged in an amniotic fluid bath. Development of EVE may allow us to treat very premature neonates without mechanical ventilation. Meanwhile, elevations in fetal inflammation are associated with adverse neonatal outcomes. In the present study, we analysed fetal survival, inflammation and pulmonary maturation in preterm lambs maintained on EVE therapy using a parallelised umbilical circuit system with a low priming volume. Methods Ewes underwent surgical delivery at 115 days of gestation (term is 150 days), and fetuses were transferred to EVE therapy (EVE group; n = 5). Physiological parameters were continuously monitored; fetal blood samples were intermittently obtained to assess wellbeing and targeted to reference range values for 2 days. Age-matched animals (Control group; n = 6) were surgically delivered at 117 days of gestation. Fetal blood and tissue samples were analysed and compared between the two groups. Results Fetal survival time in the EVE group was 27.0 ± 15.5 (group mean ± SD) hours. Only one fetus completed the pre-determined study period with optimal physiological parameters, while the other 4 animals demonstrated physiological deterioration or death prior to the pre-determined study end point. Significant elevations (p<0.05) in: i) inflammatory proteins in fetal plasma; ii) selected cytokine/chemokine mRNA expression levels in fetal tissues; and iii) histological inflammatory score in fetal lung, were observed in the EVE group compared to the Control group. There was no significant difference (p>0.05) in surfactant protein mRNA expression level between the two groups. Conclusion In this study, we achieved limited fetal survival using EVE therapy. Despite this, EVE therapy only induced a modest fetal inflammatory response and did not promote lung maturation. These data provide additional insight into markers of treatment efficacy for the assessment of future studies.


American Journal of Obstetrics and Gynecology | 2018

Low-dose betamethasone-acetate for fetal lung maturation in preterm sheep

Augusto Frederico Schmidt; Matthew W. Kemp; Judith Rittenschober-Böhm; Paranthaman S. Kannan; Haruo Usuda; Masatoshi Saito; Lucy L. Furfaro; Shimpei Watanabe; Sarah J. Stock; Boris W. Kramer; John P. Newnham; Suhas G. Kallapur; Alan H. Jobe

BACKGROUND: Antenatal steroids are standard of care for women who are at risk of preterm delivery; however, antenatal steroid dosing and formulation have not been evaluated adequately. The standard clinical 2‐dose treatment with betamethasone‐acetate+betamethasone‐phosphate is more effective than 2 doses of betamethasone‐phosphate for the induction of lung maturation in preterm fetal sheep. We hypothesized that the slowly released betamethasone‐acetate component induces similar lung maturation to betamethasone‐phosphate+betamethasone‐acetate with decreased dose and fetal exposure. OBJECTIVE: The purpose of this study was to investigate pharmacokinetics and fetal lung maturation of antenatal betamethasone‐acetate in preterm fetal sheep. STUDY DESIGN: Groups of 10 singleton‐pregnant ewes received 1 or 2 intramuscular doses 24 hours apart of 0.25 mg/kg/dose of betamethasone‐phosphate+betamethasone‐acetate (the standard of care dose) or 1 intramuscular dose of 0.5 mg/kg, 0.25 mg/kg, or 0.125 mg/kg of betamethasone‐acetate. Fetuses were delivered 48 hours after the first injection at 122 days of gestation (80% of term) and ventilated for 30 minutes, with ventilator settings, compliance, vital signs, and blood gas measurements recorded every 10 minutes. After ventilation, we measured static lung pressure‐volume curves and sampled the lungs for messenger RNA measurements. Other groups of pregnant ewes and fetuses were catheterized and treated with intramuscular injections of betamethasone‐phosphate 0.125 mg/kg, betamethasone‐acetate 0.125 mg/kg, or betamethasone‐acetate 0.5 mg/kg. Maternal and fetal betamethasone concentrations in plasma were measured for 24 hours. RESULTS: All betamethasone‐treated groups had increased messenger RNA expression of surfactant proteins A, B, and C, ATP‐binding cassette subfamily A member 3, and aquaporin‐5 compared with control animals. Treatment with 1 dose of intramuscular betamethasone‐acetate 0.125mg/kg improved dynamic and static lung compliance, gas exchange, and ventilation efficiency similarly to the standard treatment of 2 doses of 0.25 m/kg of betamethasone‐acetate+betamethasone‐phosphate. Betamethasone‐acetate 0.125 mg/kg resulted in lower maternal and fetal peak plasma concentrations and decreased fetal exposure to betamethasone compared with betamethasone‐phosphate 0.125 mg/kg. CONCLUSION: A single dose of betamethasone‐acetate results in similar fetal lung maturation as the 2‐dose clinical formulation of betamethasone‐phosphate+betamethasone‐acetate with decreased fetal exposure to betamethasone. A lower dose of betamethasone‐acetate may be an effective alternative to induce fetal lung maturation with less risk to the fetus.


Journal of Artificial Organs | 2017

Stable Control of Physiological Parameters, But Not Infection, in Preterm Lambs Maintained on Ex Vivo Uterine Environment Therapy

Yuichiro Miura; Haruo Usuda; Shinpei Watanabe; Eleanor Woodward; Masatoshi Saito; Gabrielle C. Musk; Suhas G. Kallapur; Shinichi Sato; Ryuta Kitanishi; Takashi Matsuida-machi Matsuda; John P. Newnham; Sarah J. Stock; Matthew W. Kemp

Ex vivo uterine environment (EVE) therapy is an experimental neonatal intensive care strategy wherein gas exchange is performed by membranous oxygenators attached to the umbilical vessels. Our aim was to assess the ability of a newly refined EVE system to maintain key physiological parameters in preterm lambs within optimal ranges for 48 h. EVE group; n = 6: Preterm lambs were delivered under general anesthesia at 115 ± 2 days of gestational age. Animals were submerged in a bath of artificial amniotic fluid on EVE therapy for 48 h. Physiological parameters were monitored in real-time over the length of the experiment. Control group; n = 11: Ewes carrying a single fetus (115 ± 2 days of gestational age) underwent recovery surgery to allow placement of a fetal carotid artery catheter. Fetuses received an infusion of sterile saline only. After euthanasia, EVE and Control group fetuses underwent necroscopy to perform static pressure-volume curves and for sampling of lung and cord blood plasma for molecular analyses. Five out of six fetuses in the EVE group completed the study period with key physiological variables remaining within their respective reference ranges for the duration of the 48 h study. Bacteremia was identified in four out of five EVE fetuses, and was associated with a systemic inflammatory response. Using our refined EVE therapy platform, preterm lambs were maintained in a stable physiological condition for 48 h. These findings represent a significant advance over earlier work with this system; however, the identification of bacteremia and a fetal inflammatory response suggests that further refinement to the EVE therapy platform is required.


Tohoku Journal of Experimental Medicine | 2016

Surgical Ligation for Patent Ductus Arteriosus in Extremely Premature Infants: Strategy to Reduce their Risk of Neurodevelopmental Impairment

Satoko Ito; Tadashi Matsuda; Haruo Usuda; Shimpei Watanabe; Ryuta Kitanishi; Takushi Hanita; Tatsuya Watanabe; Osamu Adachi

Surgical ligation for patent ductus arteriosus (PDA) in extremely low birth weight infants (ELBWIs) has been shown a possible association with neurodevelopmental impairment (NDI) because of its invasiveness. However, we have undergone surgical ligation for ELBWIs immediately after cyclooxygenase inhibitor failed to close a hemodynamically significant PDA (hsPDA) to maintain proper systemic circulation. We aimed to determine the effect of surgical ligation for hsPDA on NDI in ELBWIs. In enrolled 71 ELBWIs, the clinical parameters, including the developmental quotient (DQ), were collected and compared among three groups that were divided by closure mode: spontaneous closure (n = 11), cyclooxygenase inhibitor therapy (n = 37) and surgical ligation (n = 23). No significant differences in DQ at the age of 36 months among the three groups were found: Median (interquartile range): 92.0 (31.0), 89.0 (22.0) and 92.0 (24.5), respectively. In a comparison between groups of DQ < 70 (n = 15) and DQ ≥ 70 (n = 56), a significant difference was found in the parameters related to prematurity (p < 0.05 for each): gestational age [23.9 (1.70) vs. 25.4 (2.50) weeks], birth weight [595 (183) vs. 714 (192) g], Apgar score < 5 (1 min) (67% vs. 36%), and laser photocoagulation for retinopathy of prematurity (73% vs. 43%), but there was no significant association with hsPDA. Therefore, we propose that surgical ligation for hsPDA in ELBWIs should be immediately carried out for preventing future neurodevelopmental deterioration if the cyclooxygenase inhibitor failed to close hsPDA.


Animal Models for the Study of Human Disease (Second Edition) | 2017

Infection-Associated Preterm Birth: Advances From the Use of Animal Models

Matthew W. Kemp; Gabrielle C. Musk; Haruo Usuda; Masatoshi Saito

Abstract Worldwide, preterm birth (classically defined as delivery before 37 weeks’ completed gestation) is a leading cause of neonatal death. Relative to their term-born peers, survivors of preterm birth are at increased risk of developing respiratory, neurological, and cognitive disorders, with the risk of death and disease being inversely proportional to gestational age at delivery. It is increasingly clear that preterm birth is a complex, multiorigin syndrome. Intrauterine infection is considered a leading cause of early preterm birth (delivery before 32 weeks’ gestation); data from clinical and experimental studies suggest that infection accounts for upward of 40% of these high-risk preterm deliveries. This chapter is written with two aims: the first is to provide the reader with an introduction to infection-associated preterm birth, highlighting the importance of animal-based studies in advancing our understanding of this field; the second, adopting a more practical focus, is designed to provide the reader with technical insight into the use of pregnant sheep as a model organism for the study of fetal inflammatory responses to intrauterine infection and inflammation.


American Journal of Reproductive Immunology | 2017

Foetal Ureaplasma parvum bacteraemia as a function of gestation‐dependent complement insufficiency: Evidence from a sheep model of pregnancy

Matthew W. Kemp; Shatha Thanoon Ahmed; Michael L. Beeton; Matthew S. Payne; Masatoshi Saito; Yuichiro Miura; Haruo Usuda; Suhas G. Kallapur; Boris W. Kramer; Sarah J. Stock; Alan H. Jobe; John P. Newnham; Owen Bradley Spiller

Complement is a central defence against sepsis, and increasing complement insufficiency in neonates of greater prematurity may predispose to increased sepsis. Ureaplasma spp. are the most frequently cultured bacteria from preterm blood samples.


BMC Research Notes | 2013

Development of icterus gravis in a preterm infant with G71R UGT1A1 polymorphism

Akimune Kaga; Yukimune Ohkubo; Yo-hei Watanabe; Sachiko Saito; Takuma Matsuki; Haruo Usuda; Susumu Kanda; Yutaka Suzuki; Muneyuki Tanabu; Shigeo Kure

BackgroundUridine diphosphate-glucuronosyltransferase (UGT) gene family is involved in the detoxification of biomaterials and drugs in the liver. Among the UGT gene family members, only UGT1A1 is involved in bilirubin conjugation. As a result, deficient UGT1A1 activity causes jaundice. One disease that is characterized by reduced UGT1A1 activity is Gilbert’s syndrome. Two prevalent UGT1A1 polymorphisms responsible for Gilbert’s syndrome have been identified: G71R in exon 1 and A(TA)7TAA in the TATA box of the promoter region. Recently, the G71R polymorphism has been associated with breastfeeding jaundice and neonatal hyperbilirubinemia in term infants. However, its association with jaundice in very low birth weight infants (VLBWIs) has never been reported.Case presentationThe patient was a female born at 28 weeks, 4 days gestation with a birth weight of 1172 g. On day 21, intense yellowing of the skin and eyes was noted, and the patient’s total bilirubin level was 23.7 mg/dL (her direct bilirubin level was 2.1 mg/dL). Therefore, an exchange transfusion was conducted. She had neither blood type incompatibility nor a family history of constitutional jaundice. Metabolic screens for amino and organic acids were negative. No elevation of any of the examined antibody titers was noted, and no evidence of an inflammatory reaction was observed. In addition, no hematological abnormalities were detected. The direct/indirect Coombs test, irregular antibody test and red blood cell antibody dissociation test were all negative, and her thyroid function was normal. We performed sequence analysis of the UGT1A1 gene after the patient’s parents provided written informed consent. Exon 1 of the UGT1 gene on chromosome 2 was analyzed by direct sequencing. A heterozygous substitution from G to A (211G→A: G71R) in base 211 was noted.ConclusionWe speculated that this preterm infant with carrying the G71R polymorphism reduced UGT1A1 activity and developed severe jaundice that was likely triggered by factors such as breast feeding and medications. The polymorphism appears at some frequency among VLBWIs, which would necessitate adequate care of severe jaundice even after the acute phase.


PLOS ONE | 2018

Epidermal growth factor receptor inhibition with Gefitinib does not alter lung responses to mechanical ventilation in fetal, preterm lambs

T. Brett Kothe; Emily Royse; Matthew W. Kemp; Haruo Usuda; Masatoshi Saito; Gabrielle C. Musk; Alan H. Jobe; Noah H. Hillman

Background Epidermal growth factor receptor (EGFR) is important for airway branching and lung maturation. Mechanical ventilation of preterm lambs causes increases in EGFR and EGFR ligand mRNA in the lung. Abnormal EGFR signaling may contribute to the development of bronchopulmonary dysplasia. Hypothesis Inhibition of EGFR signaling will decrease airway epithelial cell proliferation and lung inflammation caused by mechanical ventilation in preterm, fetal sheep. Methods Following exposure of the fetal head and chest at 123±1 day gestational age and with placental circulation intact, fetal lambs (n = 4-6/group) were randomized to either: 1) Gefitinib 15 mg IV and 1 mg intra-tracheal or 2) saline IV and IT. Lambs were further assigned to 15 minutes of either: a) Injurious mechanical ventilation (MV) or b) Continuous positive airway pressure (CPAP) 5 cmH2O. After the 15 minute intervention, the animals were returned to the uterus and delivered after i) 6 or ii) 24 hours in utero. Results MV caused lung injury and inflammation, increased lung mRNA for cytokines and EGFR ligands, caused airway epithelial cell proliferation, and decreased airway epithelial phosphorylated ERK1/2. Responses to MV were unchanged by Gefitinib. Gefitinib altered expression of EGFR mRNA in the lung and liver of both CPAP and MV animals. Gefitinib decreased the liver SAA3 mRNA response to MV at 6 hours. There were no differences in markers of lung injury or inflammation between CPAP animals receiving Gefitinib or saline. Conclusion Inhibition of the EGFR pathway did not alter acute lung inflammation or injury from mechanical ventilation in preterm sheep.

Collaboration


Dive into the Haruo Usuda's collaboration.

Top Co-Authors

Avatar

Matthew W. Kemp

University of Western Australia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gabrielle C. Musk

University of Western Australia

View shared research outputs
Top Co-Authors

Avatar

John P. Newnham

University of Western Australia

View shared research outputs
Top Co-Authors

Avatar

Alan H. Jobe

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Yuichiro Miura

University of Western Australia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge